Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field
作者:Arthur Raitano、Tioga Martin、Chunying Zhang、Maria-Christina Malinao、Linnette Capo、Maki Ikeura、Rebecca Carroll、Jason C. Quintana、Samkeliso Dlamini、Leila Kulenovic、Eva Jahanshir、Sohye Kang、Karen Morrison、Michael Torgov、Kendall Morrison
DOI:10.1021/acs.jmedchem.3c01265
日期:2023.10.12
increased cellular retention. Like BPA, BTS uptake is mediated by the l-type amino acid transporter-1 (LAT1) but is less sensitive to natural amino acid competition. BTS can be formulated and bolus dosed at much higher levels than BPA, resulting in 2–3 times greater boron delivery in vivo. Fast blood clearance and greater tumor boron delivery result in superior tumor-to-blood ratios. BTS boron delivery
硼中子捕获疗法 (BNCT) 是一种重新出现的二元细胞水平癌症干预措施,通过癌症特异性10硼 ( 10 B) 药物和中子的相互作用而发生。我们创造了一种新的10 B 药物 3-硼醇-l-酪氨酸 (BTS),它改进了主要历史 BNCT 药物 4-硼醇-l-苯丙氨酸 (BPA) 的特性。BTS 的体外吸收量比 BPA 高 4 倍,并且细胞保留能力更强。与 BPA 一样,BTS 摄取由L型氨基酸转运蛋白 1 (LAT1) 介导,但对天然氨基酸竞争不太敏感。BTS 的配制和推注剂量可以比 BPA 高得多,从而使体内硼输送量增加 2-3 倍。快速的血液清除和更多的肿瘤硼输送导致优异的肿瘤与血液比率。BTS 硼输送似乎与 LAT1 表达相关。BTS 是一种很有前途的硼输送药物,有潜力改善现代 BNCT 干预措施。